Market Cap 95.61M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.45
Volume 125,200
Avg Vol 272,116
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 3%
Beta 1.07
Analysts Strong Sell
Price Target $7.40

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
WycklyTrader
WycklyTrader Oct. 24 at 7:53 PM
$QNCX CGEM potential base breakout with upcoming FDA catalysts. 52wk high swingS: $NUVB $RLAY $TOI $FDMT ...
0 · Reply
ADSlay
ADSlay Oct. 24 at 4:26 PM
$QNCX there are big 'reputation' costs associated for public companies to be partnering with others. They don't just randomly partner with small companies unless there is moat, especially not with someone like $QNCX who is a turnaround story, pre-revenue, and no proven product. I am sure $OPCH must've agreed to partner only after performing their thorough due-diligence. yes, no one refuses extra revenue coming in, but when you're a responsible $5 billion publicly traded company, you don't just randomly partner with anyone. there is a 'brand' image they've to protect.
0 · Reply
kb60521
kb60521 Oct. 24 at 3:22 PM
$QNCX No nothing. but again no one is selling also. Interesting. Want to see where this will take us......
0 · Reply
ADSlay
ADSlay Oct. 23 at 5:03 PM
$QNCX Anything can happen in biotech world, but why would a $5 billion company like $OPCH agree to a strategic partnership with a $100 million company like $QNCX? That alone makes $QNCX a great risk:reward opportunity besides being a Ph3 asset that has full Regulatory support from FDA.
2 · Reply
ADSlay
ADSlay Oct. 23 at 1:12 PM
Thanks for sharing. Yes, $QNCX Management regularly updates their presentation and is a great resource for research. Why would a $5 billion company associate with a $100 million company? Think why $OPCH would partner with $QNCX ? When one is such a big company, one doesn't associate with random biotech microcaps with unproven product. Think about it.
1 · Reply
ADSlay
ADSlay Oct. 20 at 4:57 PM
$QNCX CEO &CMO in Panel discussion folks🚀🚀🚀 From X today: $QNCX Investors: Looking forward to attending the 2025 Maxim Growth Summit this week where our CEO & CMO Dirk Thye, M.D., will participate in the Unlocking Value in Late-Stage/Commercial Rare Disease panel discussion.
2 · Reply
wolfhead
wolfhead Oct. 18 at 12:46 AM
$QNCX What the hell with the Huge AH drop? Phase 2 setback news?
1 · Reply
dv1809
dv1809 Oct. 17 at 10:33 PM
0 · Reply
QNCXtothemoon
QNCXtothemoon Oct. 17 at 10:01 PM
$QNCX https://ir.quincetx.com/node/9586/html
0 · Reply
kb60521
kb60521 Oct. 17 at 4:27 PM
$QNCX People are just scraping and making money with the cents. One day there won't be any shares to buy and it will be too late......
0 · Reply
Latest News on QNCX
Quince Therapeutics, Inc. - Special Call

Sep 24, 2025, 1:13 AM EDT - 4 weeks ago

Quince Therapeutics, Inc. - Special Call


Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board


Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.


Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President


WycklyTrader
WycklyTrader Oct. 24 at 7:53 PM
$QNCX CGEM potential base breakout with upcoming FDA catalysts. 52wk high swingS: $NUVB $RLAY $TOI $FDMT ...
0 · Reply
ADSlay
ADSlay Oct. 24 at 4:26 PM
$QNCX there are big 'reputation' costs associated for public companies to be partnering with others. They don't just randomly partner with small companies unless there is moat, especially not with someone like $QNCX who is a turnaround story, pre-revenue, and no proven product. I am sure $OPCH must've agreed to partner only after performing their thorough due-diligence. yes, no one refuses extra revenue coming in, but when you're a responsible $5 billion publicly traded company, you don't just randomly partner with anyone. there is a 'brand' image they've to protect.
0 · Reply
kb60521
kb60521 Oct. 24 at 3:22 PM
$QNCX No nothing. but again no one is selling also. Interesting. Want to see where this will take us......
0 · Reply
ADSlay
ADSlay Oct. 23 at 5:03 PM
$QNCX Anything can happen in biotech world, but why would a $5 billion company like $OPCH agree to a strategic partnership with a $100 million company like $QNCX? That alone makes $QNCX a great risk:reward opportunity besides being a Ph3 asset that has full Regulatory support from FDA.
2 · Reply
ADSlay
ADSlay Oct. 23 at 1:12 PM
Thanks for sharing. Yes, $QNCX Management regularly updates their presentation and is a great resource for research. Why would a $5 billion company associate with a $100 million company? Think why $OPCH would partner with $QNCX ? When one is such a big company, one doesn't associate with random biotech microcaps with unproven product. Think about it.
1 · Reply
ADSlay
ADSlay Oct. 20 at 4:57 PM
$QNCX CEO &CMO in Panel discussion folks🚀🚀🚀 From X today: $QNCX Investors: Looking forward to attending the 2025 Maxim Growth Summit this week where our CEO & CMO Dirk Thye, M.D., will participate in the Unlocking Value in Late-Stage/Commercial Rare Disease panel discussion.
2 · Reply
wolfhead
wolfhead Oct. 18 at 12:46 AM
$QNCX What the hell with the Huge AH drop? Phase 2 setback news?
1 · Reply
dv1809
dv1809 Oct. 17 at 10:33 PM
0 · Reply
QNCXtothemoon
QNCXtothemoon Oct. 17 at 10:01 PM
$QNCX https://ir.quincetx.com/node/9586/html
0 · Reply
kb60521
kb60521 Oct. 17 at 4:27 PM
$QNCX People are just scraping and making money with the cents. One day there won't be any shares to buy and it will be too late......
0 · Reply
ActaVerba
ActaVerba Oct. 17 at 1:05 PM
#QNCX Positive data from Attest study in 6-9 year old population. Neat is repeated in this population, using their higher dose of eDSP with efficacy focus on 6-9 population, although a few older have been recruited, this will not affect final efficacy. Using RmICARS - this should capture results better and prevent dilution. STRONG safety profile. Enhanced site training worldwide. FDA fast track and orphan drug status. Excellent management with proven track record. Funding to see them through TopLine. Results Q1 2026. My personal guess would be February for readout. Please note this is not financial advice and only my notes, do your own research. #Bullish #QNCX #Q12026
0 · Reply
WycklyTrader
WycklyTrader Oct. 16 at 1:55 AM
$INO & $QNCX potential base breakouts with upcoming FDA catalysts. $NIO $GME $PLUG : CGEM , AIRS insider buys + high short interest.
1 · Reply
ActaVerba
ActaVerba Oct. 14 at 2:17 PM
$QNCX Hugely exciting pipeline that this technology can be used for! How many diseases out there rely on steroids but are hampered by toxicity. Nearly everyone will know someone who has been badly bloated with various unwanted side effects from steroids during treatment. This could be massive. This is not going to stay at these prices for long. It’s P3 for AT but safety from thousands of infusions is solid. Not financial advice… But BULLISH 🚀🚀
0 · Reply
ActaVerba
ActaVerba Oct. 14 at 1:16 PM
0 · Reply
Alcryptino
Alcryptino Oct. 14 at 2:24 AM
$QNCX just 5x already, we all know you want to!
0 · Reply
McGinvests
McGinvests Oct. 10 at 3:36 PM
$CRDF just getting pounded today 😫 $QNCX $NKTX
2 · Reply
kb60521
kb60521 Oct. 10 at 2:55 PM
$QNCX wow, such a good news and such a pathetic response by market. I don't remember the numbers now, but sometime back I was doing calculations and thought the existing obligations are already making the company bit costly or something, like I was looking at 500 million or so. Do any of you think so or found the same? please share.... despite all that the company should value more than even that 500 million, I think we can give weightage to the pipeline, but more weightage to the mechanism itself. I strongly believe the mechanism is worth a lot, and many things can be achieved using the same. Please do share your thoughts......
0 · Reply
ADSlay
ADSlay Oct. 10 at 2:47 PM
$BTC $CDTX $QNCX $TE $VIR It is interesting to see both QNCX and VIR on the same list. Did you know $QNCX CEO, Dr Dirk Thye, prior to his current job, was CEO of Agenovir and had actually sold Agenovir to $VIR?
0 · Reply
dv1809
dv1809 Oct. 10 at 2:35 PM
$QNCX just an R
0 · Reply
dv1809
dv1809 Oct. 10 at 12:22 PM
$QNCX please guys, give me en TP
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 10 at 10:19 AM
WATCHLIST OCT 10 2025 $QNCX Quince Therapeutics Announces Poster Presentation Of Patient-Reported Walking Capacity In Children With Ataxia-Telangiectasia At 54th CNS Annual Meeting $VIR Vir Biotechnology Doses First Patient In Phase 1 Trial Of Dual-Masked T-Cell Engager VIR-5500 For Prostate Cancer $BTC Bitcoin, Ethereum, Dogecoin, XRP Fall Amid Government Shutdown Uncertainty: Analytics Firm Says BTC Needs To Hold This Level In Short Term $TE T1 Energy Invests In Talon Photovoltaics; Texas Tunnel Oxide Passivated Contact Solar Fabs Total 9.8 GW Backed By One Basin Build Back America Act And Section 45X Credits $CDTX WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $199
1 · Reply
CoachHendo
CoachHendo Oct. 10 at 9:08 AM
0 · Reply